TY - JOUR T1 - Systematic Review of Studies on Telomere Lengths in Patients with Multiple Sclerosis JF - medRxiv DO - 10.1101/2020.11.23.20236992 SP - 2020.11.23.20236992 AU - Jan Bühring AU - Michael Hecker AU - Brit Fitzner AU - Uwe Klaus Zettl Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/24/2020.11.23.20236992.abstract N2 - BACKGROUND Telomeres are protective cap structures at the end of chromosomes that are essential for maintening genomic stability. Accelerated telomere shortening is related to premature cellular senescence. Shortened telomere lengths (TL) have been implicated in the pathogenesis of various chronic immune-mediated and neurological diseases.OBJECTIVE We aimed to systematically review the current literature on the association of TL as a measure of biological age and multiple sclerosis (MS).METHODS A comprehensive literature search was conducted to identify original studies that presented data on TL in samples from MS patients. Quantitative and qualitative information was extracted from the articles to summarize and compare the studies.RESULTS A total of 51 articles were screened, and 7 of them were included in this review. In 6 studies, average TL were analyzed in peripheral blood cells, whereas in one study, bone marrow-derived cells were used. Four of the studies reported significantly shorter leukocyte TL in at least one MS subtype in comparison to healthy controls (p=0.003 in meta-analysis). Shorter telomeres in MS patients were found to be associated, independently of age, with greater disability, lower brain volume, increased relapse rate and more rapid conversion from relapsing to progressive MS. However, it remains unclear how telomere attrition in MS may be linked to oxidative stress, inflammation and age-related disease processes.CONCLUSIONS Despite few studies in this field, there is substantial evidence on the association of TL and MS. Variability in TL appears to reflect heterogeneity in clinical presentation and course. Further investigations in large and well-characterized cohorts are warranted. More detailed studies on TL of individual chromosomes in specific cell types may help to gain new insights into the pathomechanisms of MS.HighlightsThe relationship between aging and the pathophysiology and course of MS is not fully understoodWe have identified seven studies that analyzed telomere lengths (TL) in patients with MSOur meta-analysis revealed significantly shorter leukocyte TL in MS patients compared to healthy controlsThere is evidence that individual variability in biological aging reflects clinical heterogeneity in MSThe potential use of TL as a biomarker of age-related disease mechanisms deserves further investigationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for conducting the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.ADAlzheimer’s diseaseBMIbody mass indexCISclinically isolated syndromeCNScentral nervous systemCpGcytosine and guanine separated by a single phosphate groupDMTdisease-modifying treatmentDNAdeoxyribonucleic acidDNAmDNA methylationEDSSExpanded Disability Status ScaleHLAhuman leukocyte antigenkbkilobaseLCLlymphoblastoid cell lineLDLlow-density lipoproteinLTLleukocyte telomere lengthMHCmajor histocompatibility complexmmqPCRmonochrome multiplex qPCRMRImagnetic resonance imagingMSmultiple sclerosisMSCmesenchymal stromal cellnnumbern.c.no control groupn.i.no informationPpassage number of in vitro expansionPCRpolymerase chain reactionPPMSprimary progressive multiple sclerosisPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesQ-FISHquantitative fluorescence in situ hybridizationqPCRquantitative PCRRRMSrelapsing-remitting multiple sclerosisSsingle-copy gene signalSMDstandardized mean differenceSPMSsecondary progressive multiple sclerosisTtelomere signalTERCtelomerase RNA componentTERTtelomerase reverse trancriptaseTeSLAtelomere shortest length assayTLtelomere lengthTRFterminal restriction fragmentU-STELAuniversal single telomere length analysisvs.versus ER -